Table 5.
Selected economic evaluations of catheter ablation for ventricular tachycardia in the setting of structural heart disease.
| Study (Year) | Patient population | Analysis/Methodology | Country | Intervention vs. Comparator | Time Horizon | Currency | Incremental Cost Effectiveness Ratio | Reference |
|---|---|---|---|---|---|---|---|---|
| Coyle (2018) | Patients with ICDs and ischemic cardiomyopathy with drug-refractory VT/VF | CUA/Trial-based | Canada | Catheter ablation vs. antiarrhythmic drugs | 3 years | 2015 CDN | $34,057/QALY | (99) |
| Chen (2019) | Patients with an ICD and ischemic cardiomyopathy with refractory VT/VF | CUA/Markov decision model | United Kingdom | Catheter ablation vs. antiarrhythmic drugs | 5 years | 2018 GBP | £144,150/QALY | (100) |
| Calkins (2000) | Patients with an ICD and ischemic cardiomyopathy with VT/VF | CUA/Markov model | United States | Catheter ablation versus amiodarone | 5 years | 1998 USD | $20,923/QALY | (101) |
CDN, Canadian; CUA, cost utility analysis; ICD, implantable cardioverter defibrillator; GBP, British Pound Sterling; QALY, quality adjusted life years; LV, left ventricular; VF, ventricular fibrillation; VT, ventricular tachycardia.